Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
AstraZeneca
Mallinckrodt
Colorcon
Boehringer Ingelheim

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 8,551,937

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,551,937
Title:Peptide having an extending action for half-life of object peptide in plasma
Abstract: An isolated chimeric peptide consisting of one or two added peptides and an object peptide wherein the added peptide is bonded to the N-terminus, the C-terminus or both of the object peptide, wherein if the added peptides are bound to both terminals, the two added peptides may be the same or different; and physiological activity of the object peptide is still retained, wherein the object peptide is a natural physiologically active peptide selected from the group consisting of an atrial natriuretic peptide, a brain natriuretic peptide, a C-type natriuretic peptide, motilin, a glucagon-like peptide 1, parathyroid hormone, and calcitonin, or a derivative of any thereof, wherein the derivative has one or more amino acid(s) deleted from the amino acid sequence of a natural physiologically active peptide and has the desired physiological activity.
Inventor(s): Wakabayashi; Naomi (Gunma, JP), Sato; Seiji (Gunma, JP)
Assignee: Daiichi Sankyo Company, Limited (Tokyo, JP)
Application Number:12/675,961
Patent Claims:1. An isolated chimeric peptide consisting of one or two added peptides and an object peptide wherein the added peptide is bonded to the N-terminus, the C-terminus or both of the object peptide, wherein if the added peptides are bound to both terminals, the two added peptides may be the same or different; the added peptide is (I), (I) a peptide represented by the formula B, A-B, B-C or A-B-C in which A, B and C each is represented by the following (1), (2) and (3); (1) A is a peptide selected from the group consisting of a peptide consisting of an amino acid sequence of amino acid numbers 1 to 4 in SEQ ID No: 34, a peptide consisting of an amino acid sequence of amino acid numbers 1 to 8 in SEQ ID No.: 67, and a peptide consisting of an amino acid sequence where 1 to 6 amino acid(s) in the above amino acid sequence is/are deleted, substituted, and/or added; (2) B is a peptide represented by the formula 1: (Wk-Xl-Y-Zm-Wn)-(Wo-Xp-Y-Zq-Wr)s, wherein in the formula 1, W is a basic amino acid selected from Arg Lys; X and Z are the same or different and selected from the group consisting of Ser, Pro, Leu, Phe, Ala, Thr, Gly, Val, Tyr, and His; Y is Glu or Asp; k is 1 or 2; l is an integer of 4.gtoreq.l.gtoreq.0; m is an integer of 2.gtoreq.m.gtoreq.0; 4.gtoreq.l+m.gtoreq.0; n is 1 or 2; o is an integer of 2.gtoreq.o.gtoreq.0; p is an integer of 4.gtoreq.p.gtoreq.0; q is an integer of 2.gtoreq.q.gtoreq.0; 4.gtoreq.p+q.gtoreq.0; r is 1 or 2; and s is 0 or 1; and (3) C is a peptide selected from the group consisting of a peptide consisting of amino acid numbers 10 to 17 in SEQ ID No: 34, a peptide consisting of amino acid numbers 14 to 17 in SEQ ID No: 67, a peptide consisting of an amino acid sequence where 1 to 6 amino acid(s)in the above amino acid sequence is/are deleted, and/or added, and/or 1 to 4 amino acid(s) in the above amino acid sequence is/are substituted, and the peptide contains 4 to 9 amino acid sequences being able to form a helix structure, and physiological activity of the object peptide is still retained, wherein the object peptide is a natural physiologically active peptide selected from the group consisting of an atrial natriuretic peptide, a brain natriuretic peptide, a C type natriuretic peptide, motilin, glucagon like peptide 1, parathyroid hormone, and calcitonin, or a derivative thereof, wherein the derivative has one or more amino acid(s) deleted from the amino acid sequence of a natural physiologically active peptide and has the desired physiological activity.

2. The chimeric peptide according to claim 1, wherein the added peptide is bonded to the N-terminus of the object peptide.

3. The chimeric peptide according to claim 1, wherein the added peptide is bonded to the C-terminus of the object peptide.

4. The chimeric peptide according to claim 1, wherein the added peptide is bonded to both termini of the object peptide.

5. The chimeric peptide according of claim 1, wherein the object peptide is an atrial natriuretic peptide, a C type natriuretic peptide, or motilin, or derivatives thereof, wherein the derivative has one or more amino acid(s) deleted from the amino acid sequence of natural physiologically active peptide and has the desired physiological activity.

6. The chimeric peptide according to claim 1, wherein s is 1, o is 0, p is 0, q is 0, and r is 2 in the formula 1.

7. The chimeric peptide according to claim 1, wherein C has a Pro sequence between its terminal and the amino acid sequence being able to form a helix structure.

8. The chimeric peptide according to claim 1, wherein A is selected from the group consisting of SPEHQRVQQR, EHQRVQQR, QRVQQR, VQQR, VQQ, QR, and RPQLKAPP.

9. The chimeric peptide according to claim 1, wherein C is selected from the group consisting of PPAKLQPR, RQQV, PPAKLQ, PPAK, AKLQPR, AKLAALKA, PPAKLAALKA, PPAELAALEA, PPAELAALKA, and PPALQPR.

10. The chimeric peptide according to claim 1, wherein B is selected from the group consisting of KESKK, KKSEK, KEKK, KEFKK, KETKK, KEPKK, KELKK, KEAKK, KDSKK, KRDSRR, KGESKK, KESGKK, KGGESKK, KGGESGKK, KKAYSPDKERK, and KVVDHPKR.

11. The chimeric peptide according to claim 1, wherein the added peptide consists of amino acid sequence selected from the group consisting of amino numbers 23 to 39 of SEQ ID No: 106 (VQQRKESKKPPAKLQPR), amino acid numbers 1 to 17 in SEQ ID No: 108 (RPQLKAPPKKSEKRQQV), amino acid numbers 13 to 35 in SEQ ID No: 111 (SPEHQRVQQRKESKKPPAKLQPR), amino acid numbers 13 to 33 in SEQ ID No: 112 (EHQRVQQRKESKKPPAKLQPR), amino acid numbers 13 to 31 in SEQ ID No: 113 (QRVQQRKESKKPPAKLQPR), amino acid numbers 13 to 27 in SEQ ID No: 115 (QRKESKKPPAKLQPR), amino acid numbers 13 to 25 in SEQ ID No: 116 (KESKKPPAKLQPR), amino acid numbers 13 to 27 in SEQ ID No: 118 (VQQRKESIKKPPAKLQ), amino acid numbers 13 to 25 in SEQ ID No: 119 (VQQRKESKKPPAK), amino acid numbers 13 to 23 in SEQ ID No: 120 (VQQRKESKKPP), amino acid numbers 13 to 21 in SEQ ID No: 121 (VQQRKESKK), amino acid numbers 13 to 28 in SEQ ID No: 131 (VQQRKEKKPPAKLQPR), amino acid numbers 13 to 29 in SEQ ID No: 132 (VQQRKEFKKPPAKLQPR), amino acid numbers 13 to 29 in SEQ ID No: 133 (VQQRKETKKPPAKLQPR), amino acid numbers 13 to 29 in SEQ ID No: 134 (VQQRKEPKKPPAKLQPR), amino acid numbers 13 to 29 in SEQ ID No: 135 (VQQRKELKKPPAKLQPR), amino acid numbers 13 to 29 in SEQ ID No: 136 (VQQRKEAKKPPAKLQPR), amino acid numbers 13 to 29 in SEQ ID No: 139 (VQQRKDSKIKPPAKLQPR), amino acid numbers 13 to 29 in SEQ ID No: 141 (VQQKRDSRRPPAKLQPR), amino acid numbers 13 to 29 in SEQ ID No: 142 (VQQKKSEKRPPAKLQPR), amino acid numbers 13 to 30 in SEQ ID No: 143 (VQQRKGESKKPPAKLQPR), amino acid numbers 13 to 30 in SEQ ID No: 144 (VQQRKESGKKPPAKLQPR), amino acid numbers 13 to 31 in SEQ ID No: 145 (VQQRKGGESKKPPAKLQPR), amino acid numbers 13 to 32 in SEQ ID No: 146 (VQQRKGGESGKKPPAKLQPR), amino acid numbers 13 to 27 in SEQ ID No: 147 (VQQRKESKKAKLQPR), amino acid numbers 13 to 29 in SEQ ID No: 148 (VQQRKESKKAKLAALKA), amino acid numbers 13 to 31 in SEQ ID No: 149 (VQQRKESKKPPAKLAALKA), amino acid numbers 13 to 31 in SEQ ID No: 150 (VQQRKESKKPPAELAALEA), amino acid numbers 13 to 31 in SEQ ID No: 151 (VQQRKESKKPPAELAALKA), amino acid numbers 13 to 27 in SEQ ID No: 154 (KESKKPPAKLAALKA), amino acid numbers 13 to 33 in SEQ ID No: 155 (VQQKKAYSPDKERKPPALQPR), amino acid numbers 13 to 34 in SEQ ID No: 156 (VQQKKAYSPDKERKPPAKLQPR), and amino acid numbers 27 to 36 min SEQ ID No: 158 (QRKVVDHPKR).

12. An isolated chimeric peptide comprising an amino acid sequence shown in SEQ ID Nos: 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 118, 119, 120, 121, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 139, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 154, 155, 156, or 157.

13. The isolated chimeric peptide consisting of an amino acid sequence shown in SEQ ID Nos: 106, 107, 108, 109, 110, 111, 1.12, 113, 114, 115, 116, 118, 119, 120, 121, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 139, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 154, 155, 156, 157, or 158.

14. The chimeric peptide according to claim 13, consisting of an amino acid sequence shown in SEQ ID NO: 125 or 157.

15. A pharmaceutical composition in which the chimeric peptide of claim 1 or a pharmaceutically acceptable salt thereof is an effective ingredient.

16. A pharmaceutical composition comprising a. chimeric peptide or a pharmaceutically acceptable salt thereof as an effective ingredient, wherein the chimeric peptide is the peptide of claim 5.

17. The pharmaceutical composition according to claim 16, wherein the object peptide in the chimeric peptide is an atrial natriuretic peptide or a derivative thereof, wherein the derivative has one or more amino acid(s) deleted from the amino acid sequence of national physiologically active peptide and has the desired physiological activity.

18. The pharmaceutical composition according to claim 17, wherein it is for the treatment of diseases selected from acute cardiac insufficiency, chronic cardiac insufficiency, obliterative arteriosclerosis, ischemic cardiac disease, hypertension, edema disease, myocardial disease, retinitis, diabetic renal disease, nephrosclerosis, and myocardial infarction.

19. The pharmaceutical composition according to claim 16, wherein the object peptide in the chimeric peptide is a C type natriuretic peptide or a derivative thereof, wherein the derivative has one or more amino acid(s) deleted from the amino acid sequence of national physiologically active peptide and has the desired physiological activity.

20. The pharmaceutical composition according to claim 19, wherein it is for the treatment of diseases selected from atypical chondrodysplasia, restenosis after PTCA after coronary artery stenosis, pulmonary hypertension, peripheral artery obliterative disease, osteoarthritis, rheumatoid arthritis, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, myocardial infarction, and myocarditis.

21. The pharmaceutical composition according to claim 16, wherein the object peptide in the chimeric peptide is motilin or a derivative thereof, wherein the derivative has one or more amino acid(s) deleted from the amino acid sequence of a natural physiologically active peptide and has the desired physiological activity.

22. The pharmaceutical composition according to claim 21, wherein it is for the treatment of diseases selected from functional dyspepsia, reflux esophagitis, diabetic gastroparesis, constipation-type irritable bowel syndrome, chronic pseudoileus, postoperative ileus, chronic gastritis, and atrophic gastritis.

23. A process for producing a chimeric peptide consisting of one or two added peptides and an object peptide as defined in claim 1, characterized by a step of bonding the added peptide to the N-terminus, the C-terminus, or both of the object peptide, wherein if the added peptides are bound to both terminals, the added peptides may be the same or different; wherein the added peptide is (I), (I) a peptide represented by the formula B, A-B, B-C or A-B-C in which A, B and C each is represented by the following (1), (2) and (3); (1) A is a peptide selected from the group consisting of a peptide consisting of an amino acid sequence of amino acid numbers 1 to 4 in SEQ ID No. 34, a peptide consisting of an amino acid sequence of amino acid numbers 1 to 8 in SEQ ID No.: 67, and a peptide consisting of an amino acid sequence where 1 to 6 amino acid(s) in the above amino acid sequence is/are deleted, substituted, and/or added; (2) B is a peptide represented by the formula 1: (Wk-Xl-Y-Zm-Wn)-(Wo-Xp-Y-Zq-Wr)s, wherein in the formula 1, W is a basic amino acid selected from Arg and Lys; X and Z are the same or different and selected from the group consisting of Ser, Pro, Leu, Phe, Ala, Thr, Gly, Val, Tyr, and His; Y is Glu or Asp; k is 1 or 2; l is an integer of 4.gtoreq.l.gtoreq.0; m is an integer of 2.gtoreq.m.gtoreq.0; 4.gtoreq.l+m.gtoreq.0; n is 1 or 2; o is an integer of 2.gtoreq.o.gtoreq.0; p is an integer of 4.gtoreq.p.gtoreq.0; q is an integer of 2.gtoreq.q.gtoreq.0; 4.gtoreq.p+q.gtoreq.0; r is 1 or 2; and s is 0 or 1; and (3) C is a peptide selected from the group consisting of a peptide consisting of amino acid numbers 10 to 17 in SEQ ID No: 34, a peptide consisting of amino acid numbers 14 to 17 in SEQ ID No: 67, a peptide consisting of an amino acid sequence where 1 to 6 amino acid(s)in the above amino acid sequence is/are deleted, and/or added, and/or 1 to 4 amino acid(s) in the above amino acid sequence is/are substituted, and the peptide contains 4 to 9 amino acid sequences being able to form a helix structure.

24. The process according to claim 23, wherein the added peptide is bonded to the N-terminus of the object peptide.

25. The process according to claim 23, wherein the added peptide is bonded to the C-terminus of the object peptide.

26. The process according to claim 23, wherein the added peptide is bonded to both termini of the object peptide.

27. The process according of claim 23, wherein the object peptide is a natriuretic peptide, motilin, or a derivative thereof, wherein the derivative has one or more amino acid(s deleted from the amino acid sequence of a natural physiologically active peptide and has the desired physiological activity.

28. The process according to claim 27, wherein the object peptide is an atrial natriuretic peptide or a derivative thereof, wherein the derivative has one or more amino acid(s) deleted from the acid sequence of a natural physiologically active peptide and has the desired physiological activity.

29. The process according to claim 27, wherein the object peptide is a C type natriuretic peptide or a derivative thereof, wherein the derivative has one or more amino acid(s) deleted from the amino acid sequence of a natural physiologically active peptide and has the desired physiological activity.

30. The process according to claim 27, wherein the object peptide is motilin or a derivative thereof, wherein the derivative has one or more amino acid(s) deleted from the amino acid sequence of a natural physiologically active peptide and has the desired physiological activity.

31. A method for the treatment of a disease that is able to be treated by the object peptide contained in a pharmaceutical composition according to claim 18, comprising administration of the pharmaceutical composition to an individual, wherein the disease is a disease selected from acute cardiac insufficiency, chronic cardiac insufficiency, obliterative arteriosclerosis, ischemic cardiac disease, hypertension, edema disease, myocardial disease, retinitis, diabetic renal disease, nephrosclerosis, and myocardial infarction.

32. A method for the treatment of a disease that is able to be treated by the object peptide contained in a pharmaceutical compostion, comprising administration of the pharmaceutical composition to an individual, wherein the pharmaceutical compostion is the composition of claim 19, and, wherein the disease is a disease selected from atypical chondrodysplasia, restenosis after PTCA after coronary artery stenosis, pulmonary hypertension, peripheral artery obliterative disease, osteoarthritis, rheumatoid arthritis, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, myocardial infarction and myocarditis.

33. A method for the treatment of a disease that is able to be treated by the object peptide contained in a pharmaceutical composition, comprising administration of the pharmaceutical composition to an individual, wherein the pharmaceutical composition is the pharmaceutical composition of claim 21, and, wherein the disease is a disease selected from functional dyspepsia, reflux esophagitis, diabetic gastroparesis, constipation-type irritable bowel syndrome, chronic pseudoileus, postoperative ileus, chronic gastritis and atrophic gastritis.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Mallinckrodt
Dow
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.